source
- Why we left the FDA: Six former officials share their storiesIn this week's STATus Report, hear from six former FDA officials on why they left the agency.STAT · 3mo ago↗ source
- Odyssey, on second try, snags $279M in an IPOAfter withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…BioPharma Dive · 3mo ago↗ source
- Dr Sznol on Optimal Treatment Sequencing in MelanomaMario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.onclive · 3mo ago↗ source